GHK-Cu injection reactions: what the science says about lumps and bruising

What did @shareepage1 actually say?

She said she's stopping GHK-Cu injections because of "golf ball sized lumps" at her injection sites on her butt and hips that lasted weeks and were painful to the touch. She also asked whether applying GHK-Cu topically during microneedling, in place of PRP, might be a safer alternative. These are two separate claims worth examining on their own terms.

To her credit, she's not overselling anything. She's describing a real adverse reaction, asking her audience if they've experienced the same thing, and questioning whether to continue. That's a reasonable response to what sounds like a genuinely uncomfortable situation. The microneedling suggestion, though, is where things get more speculative.

Does the science back this up?

Yes and no. Injection site reactions with subcutaneous peptides are well-documented, though the severity she's describing is on the more serious end of the spectrum. Lumps lasting "weeks" and reaching that size suggest something beyond routine post-injection inflammation.

GHK-Cu, or copper tripeptide-1, has legitimate research behind its wound-healing and anti-inflammatory properties when applied topically. Pickart and Margolina (2018, Cosmetics) reviewed decades of data showing GHK-Cu accelerates wound repair and stimulates collagen synthesis in skin tissue. But nearly all of that research is on topical application. Injectable GHK-Cu as a systemic therapy sits in a much thinner evidence base. There are no large randomized controlled trials on subcutaneous GHK-Cu injection in humans that document standard injection site tolerability profiles. The reaction she's describing could reflect the peptide itself, the carrier solution, the compounding quality, injection technique, or some combination of all four.

On the microneedling idea: a small body of research does suggest topical copper peptides enhance skin remodeling when paired with microneedling, as the micro-channels improve penetration depth. But replacing PRP with GHK-Cu is not a validated clinical protocol. PRP's mechanism involves autologous growth factors. GHK-Cu is a synthetic copper complex. They are not interchangeable.

What did they get wrong (or right)?

She got the reaction right. Golf ball-sized subcutaneous lumps that persist for weeks are not normal injection site responses and stopping the protocol was the correct call. That kind of reaction warrants a conversation with a prescribing clinician, not a workaround. She appears to have skipped that step.

What she got wrong, or at least left dangerously vague, is framing microneedling with GHK-Cu as a straightforward substitute. The suggestion to have an esthetician "use this as though it's the PRP" conflates two entirely different modalities. Estheticians are not licensed to administer prescription peptides in most states, and using a compounded injectable peptide in a microneedling setting introduces contamination and dosing risks that she doesn't acknowledge. The casual tone of "thinking of doing that, has anyone ever tried that" is exactly how unvetted protocols spread on social media.

She also implies the lumps mean the peptide "is working," which is not a reasonable assumption. Tissue reaction is not the same as therapeutic effect. There's no evidence that painful subcutaneous granulomas indicate GHK-Cu efficacy.

What should you actually know?

Subcutaneous injection reactions fall into a few categories: immediate (histamine-driven), delayed hypersensitivity, and foreign body granulomas. Lumps that persist for weeks are more consistent with the latter two. A 2021 review in the Journal of Clinical and Aesthetic Dermatology noted that compounded injectable products carry elevated contamination and pH-variance risks compared to FDA-approved formulations, which can directly cause granulomatous tissue responses.

If you are using compounded peptides subcutaneously and develop persistent lumps, redness, or pain lasting more than a few days, that is a clinical signal that requires evaluation, not a social media poll. A telehealth provider or in-person physician needs to assess whether you're dealing with an infection, a granuloma, or a hypersensitivity response.

The topical and microneedling applications of GHK-Cu are a legitimately different conversation with better safety data behind them. But that does not mean any formulation marketed as injectable GHK-Cu is safe to apply to open microneedling channels. Formulation matters. Sterility matters. The route of administration changes the risk profile entirely.

• Do not continue a subcutaneous injection protocol that is causing week-long lumps without medical evaluation.
• Estheticians cannot and should not be administering prescription compounded peptides in any context.
• GHK-Cu topical research is real but does not validate injectable use.
• "It might be working" is not a justification for a tissue reaction of this severity.